SINTX TECHNOLOGIES, INC.
SINT Healthcare Medical Devices
SINTX TECHNOLOGIES, INC.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 64.7% from fiscal 2024. In the quarter to June 2026, revenue grew 199.3%, EPS grew 17.6%, free cash flow fell 38.6% and total debt fell 6.42%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SINT
SINTX TECHNOLOGIES, INC. (SINT) Altman Z-score
SINTX TECHNOLOGIES, INC.'s Altman Z-score for fiscal 2025 is −45.42, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −45.42 | 0.50 |
| FY2024 | −45.92 | (18.89) |
| FY2023 | −27.03 | (1.57) |
| FY2022 | −25.46 | (10.50) |
| FY2021 | −14.96 | (7.20) |
| FY2020 | −7.77 | 29.65 |
| FY2019 | −37.42 | (279,683.99) |
| FY2016 | 279646.58 | 150,599.95 |
| FY2015 | 129046.62 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.20 | — | 0.24 | |
| Retained earnings / total assets | (30.73) | — | −43.02 | |
| EBIT / total assets | (1.13) | — | −3.72 | |
| Market value of equity / total liabilities | 1.63 | — | 0.98 | |
| Sales / total assets | 0.11 | — | 0.11 | |
| Altman Z-score | Distress zone | −45.42 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −105.96 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| IRIX IRIDEX Corporation compare | −2.0× |
| CTSO Cytosorbents Corporation compare | −9.2× |
| LFWD Lifeward Ltd. compare | −18.8× |
| HSCS HeartSciences Inc. compare | −27.9× |
| ALUR Allurion Technologies, Inc. compare | −29.6× |
| BTCY Biotricity Inc. compare | −33.3× |
| PETV PetVivo Holdings, Inc. compare | −38.6× |
| SINT SINTX TECHNOLOGIES, INC. | −45.4× |
| RBOT Vicarious Surgical Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets